Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
14(4)
Published: Dec. 25, 2024
Abstract
Oral
formulation
is
the
ideal
treatment
method
for
inflammatory
bowel
disease
(IBD)
therapy,
but
mucosal
damage
and
diarrhea
symptoms
impede
drug
retention
around
region,
severely
limiting
IBD
therapeutic
efficacy.
To
address
this,
an
oral
astaxanthin
(Ast)
precise
delivery
developed
with
selective
Ast
anchoring
region
by
novel
lactoferrin
(LF)‐responsive
flocculation.
This
also
heightens
apparent
solubility
of
minimized
edible
safety
risks
raw
materials.
For
in
vivo
exhibits
remarkable
outcomes,
including
a
significant
increase
colon
length
100%
survival
rate.
Furthermore,
it
verified
that
mechanism
primarily
attributed
to
improved
immunoregulation,
epithelial
repair,
gut
microbiota
remodeling
after
LF‐responsive
effective
inflammatory‐responsive
design
instructive
valuable
develop
more
systems
therapy.
Nano-Micro Letters,
Journal Year:
2025,
Volume and Issue:
17(1)
Published: Feb. 6, 2025
Abstract
The
use
of
microneedles
(MNs)
has
been
established
as
an
effective
transdermal
drug
delivery
strategy
that
extensively
deployed
for
treating
various
diseases,
including
skin
diseases.
MNs
can
surpass
the
constraints
conventional
methods
by
their
superior
safety
and
efficacy
through
precise
targeting,
while
simultaneously
enabling
painless
delivery.
Currently,
are
increasingly
used
carriers
delivery,
with
loading
insoluble
drugs
to
improve
treatment
efficiency
or
combining
bioactive
substances
construction
efficient
system
maximize
effects
substances.
preparation
diverse,
them
meet
requirements
most
applications.
emergence
addressed
shortcomings
associated
drugs,
expanded
applications
substances,
improved
in
clinical
practice.
This
review
summarizes
current
information
on
application
a
variety
such
psoriasis,
vitiligo,
alopecia,
hypertrophic
scarring,
atopic
dermatitis,
melanoma,
acne,
infections.
future
opportunities
diseases
also
discussed.
Despite
substantial
progress
vectors,
issues
low
poor
mechanical
strength
during
remain
main
challenges.
Therefore,
implementation
MNs-based
therapies
remains
limited,
highlighting
key
research.
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: July 31, 2024
Hyperuricemia
is
associated
with
an
increased
risk
of
gout,
hypertension,
diabetes,
and
cardiovascular
diseases.
Most
mammals
maintain
normal
serum
uric
acid
(SUA)
via
urate
oxidase
(Uox),
enzyme
that
metabolizes
poorly-soluble
UA
to
highly-soluble
allantoin.
In
contrast,
Uox
became
a
pseudogene
in
humans
apes
over
the
long
course
evolution.
Here
we
demonstrate
atavistic
strategy
for
treating
hyperuricemia
based
on
endogenous
expression
hepatocytes
mediated
by
mRNA
(mUox)
loaded
ionizable
lipid
nanoparticle
termed
iLAND.
mUox@iLAND
allows
effective
transfection
protein
vitro.
A
single
dose
lowers
SUA
levels
several
weeks
two
female
murine
models,
including
novel
long-lasting
model,
which
also
confirmed
metabolomics
analysis.
Together
excellent
safety
profiles
observed
vivo,
proposed
agent
demonstrates
substantial
potential
therapy
prevention
conditions.
Urate
(Uox)
lost
its
function
during
authors
propose
treat
using
proprietary
load
mRNA,
reduced
effectively
animal
models.
Signal Transduction and Targeted Therapy,
Journal Year:
2025,
Volume and Issue:
10(1)
Published: March 10, 2025
Abstract
The
ability
of
small
nucleic
acids
to
modulate
gene
expression
via
a
range
processes
has
been
widely
explored.
Compared
with
conventional
treatments,
acid
therapeutics
have
the
potential
achieve
long-lasting
or
even
curative
effects
editing.
As
result
recent
technological
advances,
efficient
delivery
for
therapeutic
and
biomedical
applications
achieved,
accelerating
their
clinical
translation.
Here,
we
review
increasing
number
classes
most
common
chemical
modifications
platforms.
We
also
discuss
key
advances
in
design,
development
application
each
platform.
Furthermore,
this
presents
comprehensive
profiles
currently
approved
drugs,
including
11
antisense
oligonucleotides
(ASOs),
2
aptamers
6
siRNA
summarizing
modifications,
disease-specific
mechanisms
action
strategies.
Other
candidates
whose
trial
status
recorded
updated
are
discussed.
consider
strategic
issues
such
as
important
safety
considerations,
novel
vectors
hurdles
translating
academic
breakthroughs
clinic.
Small
produced
favorable
results
trials
address
previously
“undruggable”
targets,
suggesting
that
they
could
be
useful
guiding
additional
candidates.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(50), P. 33907 - 33921
Published: Dec. 3, 2024
Acute
liver
failure
(ALF)
is
a
serious
global
disease
characterized
by
rapid
onset
and
high
mortality.
Currently,
the
clinical
treatment
of
ALF
faces
considerable
hurdles
due
to
limited
medication
options
scarcity
transplants.
Despite
biomacromolecules
such
as
hepatocyte
growth
factor
(HGF)
glutathione
(GSH)
having
been
applied
for
symptom
relief
in
clinic,
they
still
face
substantial
challenges
including
poor
stability,
difficulty
acting
on
intracellular
targets,
inadequate
therapeutic
outcome.
In
this
work,
taking
advantage
innate
targeting
regenerative
capabilities
mesenchymal
stem
cells
(MSCs),
we
harnessed
MSC-derived
exosomes
natural
bioactive
carriers
simultaneous
delivery
HGF
GSH,
forming
fully
nanodrug
termed
HG@Exo.
Impressively,
HG@Exo
demonstrated
potent
effects
against
both
carbon
tetrachloride
(CCl
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 9, 2025
Abstract
Ulcerative
colitis
(UC)
is
a
chronic
disease.
A
significant
challenge
for
the
management
of
UC
to
achieve
delivery
drugs
multi‐layer
colonic
barriers,
as
existing
are
difficult
penetrate
these
depths.
In
this
study,
novel
drug
system
using
yeast
cell
wall
microparticles
(YPs)
developed
co‐encapsulate
Bacillus
subtilis
(BS)
and
Rhein
(Rh)
termed
Rh‐YBS.
This
specifically
targets
microfold
cells,
enabling
direct
BS
submucosa.
Additionally,
Rh
enhances
colonization
in
submucosa
through
floral
regulation.
Studies
indicate
that
Rh‐YBS
can
effectively
reach
proliferate
within
vivo.
DSS‐induced
mouse
model,
stimulates
CGRP‐related
neural
pathway;
activation
leads
increased
CGRP
secretion,
prompting
goblet
cells
secrete
mucus
thereby
repairing
mucosa.
Furthermore,
also
provide
preventive
benefit
against
UC.
summary,
represents
an
innovative
mucosal
repair
treatment,
activating
unique
mechanism
involving
pathway.
